Condition: Carcinoma, Non-Small Cell Lung · Sponsor: AstraZeneca
The purpose of ARTEMIDE-Lung04 is to assess the efficacy and safety of rilvegostomig compared with pembrolizumab monotherapy as 1L treatment in participants with mNSCLC and whose tumors express PD-L1.
This description comes directly from the study's public registry record.
AstraZeneca Clinical Study Information Center · 1-877-240-9479 · information.center@astrazeneca.com
Always discuss trial participation with your own doctor first.
| Research Site | La Mesa, California, United States | Not Yet Recruiting |
| Research Site | Los Alamitos, California, United States | Not Yet Recruiting |
| Research Site | Farmington, Connecticut, United States | Recruiting |
| Research Site | Newark, Delaware, United States | Recruiting |
| Research Site | Bay Pines, Florida, United States | Recruiting |
| Research Site | Clearwater, Florida, United States | Recruiting |
| Research Site | St. Petersburg, Florida, United States | Recruiting |
| Research Site | Marietta, Georgia, United States | Recruiting |
| Research Site | Chicago, Illinois, United States | Recruiting |
| Research Site | Decatur, Illinois, United States | Recruiting |
| Research Site | Des Moines, Iowa, United States | Recruiting |
| Research Site | Waterloo, Iowa, United States | Not Yet Recruiting |
+ 284 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06868277